微爆发VNS治疗在耐药焦点和泛性的可行性研究
Cornelia Drees1, Pegah Afra2, Ryan Verner3
1Mayo Clinic Arizona, Department of Neurology, Phoenix, AZ, USA; University of Colorado School of Medicine, Department of Neurology, Aurora, CO, USA.
Brain stimulation
|March 18, 2024
概括
高频微爆发神经刺激 (μVNS) 显示出对抗药性的有前途,显著减少发作和良好的耐受性. 需要进一步的试验来确认其作为一种新疗法替代品的有效性.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 生物医学工程 生物医学工程
背景情况:
- 使用低频率 (≤30 Hz) 的神经刺激 (VNS) 是对抗药性 (DRE) 的已知治疗方法.
- 本研究介绍了一种研究中的高频VNS范式,称为微爆VNS (μVNS),利用短,高频的电脉冲爆发.
研究的目的:
- 评估新型高频μVNS范式的初始安全性和有效性.
- 评估DRE患者中μVNS的性能.
主要方法:
- 一项探索性可行性研究招募了33名患有焦点发作或泛发作的参与者.
- 使用fMRI协议实现了个性化的μVNS剂量.
- 参与者被监测不良事件和发作频率长达12个月.
主要成果:
- μVNS耐受性良好,不良事件与低频VNS相似,严重程度下降.
- 12个月后,所有参与者均观察到平均发作频率减少61.3%.
- 12个月的响应率 (≥50%的减少) 为63.3%,超级响应率 (≥80%的减少) 为40%.
结论:
- 微爆发VNS (μVNS) 证明了安全性和潜力,作为DRE的治疗替代方案.
- 需要在随机对照试验中进行进一步的研究,以确定最佳参数和患者适应性.
相关概念视频
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...